COMMUNIQUÉS West-GlobeNewswire
-
JDCA Releases First-of-Its-Kind Report of Companies Working on a Diabetes Cure
17/02/2026 -
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
17/02/2026 -
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
17/02/2026 -
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
17/02/2026 -
Salvin® Dental Specialties Partners With Preat® to Offer PreatLoc™ Overdenture Attachment System
17/02/2026 -
Codexis to Participate in TD Cowen 46th Annual Health Care Conference
17/02/2026 -
Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer
17/02/2026 -
Solera Health Launches Intervention-Based Behavioral Health Network to Expand Whole-Person Care
17/02/2026 -
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
17/02/2026 -
Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average
17/02/2026 -
Lite Strategy Reports Fiscal 2026 Second Quarter Results
17/02/2026 -
Earth Science Tech, Inc. Announces Initiatives to Advance Public Company Strategy; Expects Approximately $1.4 Million in Annualized Savings and Fiscal 2026 Net Income Growth of More Than 40%, from $3.3 Million to $4.7 Million
17/02/2026 -
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
17/02/2026 -
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
17/02/2026 -
Earth Science Tech, Inc. (ETST) Upgrades Audit Capabilities, Engages Semple, Marchal & Cooper, LLP as Independent PCAOB Auditor to Support Continued Expansion
17/02/2026 -
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
17/02/2026 -
Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
17/02/2026 -
ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance
17/02/2026 -
Sienna Continues Platform Growth in Ontario and British Columbia
17/02/2026
Pages